Question 1

What is Climb Bio's P/S ratio?

Accepted Answer

Climb Bio (CLYM) P/S ratio is currently not available. Revenue is essentially never negative, so a missing P/S almost always reflects a data gap (recent IPO, restatement, or restated currency) rather than a fundamental issue.

Question 2

How is the P/S ratio calculated?

Accepted Answer

P/S = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Revenue, or equivalently Share Price ÷ TTM Revenue Per Share. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/S ratio?

Accepted Answer

The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.

Question 4

What is a good P/S ratio for Climb Bio?

Accepted Answer

A "good" P/S depends heavily on profit margin and growth: software and other high-margin businesses often command 5–15× sales, while low-margin retailers and commodity producers typically trade below 1×. Compare against sector peers rather than absolute thresholds. For Climb Bio specifically, the relevant sector benchmark is the current sector median of 3.7×.

Question 5

Why does Climb Bio's P/S ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (revenue). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.

Question 6

Why is Climb Bio's P/S ratio not available?

Accepted Answer

Revenue is essentially never negative, so a missing P/S almost always reflects a data gap (recent IPO, restatement, or restated currency) rather than a fundamental issue.


2025	$269.48M	$0.00	—	—	Dec 31, 2025
2024	$116.53M	$0.00	—	—	Dec 31, 2024
2023	$213.86M	$0.00	—	—	Dec 31, 2023
2022	$206.50M	$0.00	—	—	Dec 31, 2022
2021	$205.35M	$0.00	—	—	Dec 31, 2021
2020	$91.31M	$0.00	—	—	Dec 31, 2020


AptarGroup (ATR)	2.1×
Becton, Dickinson and (BDX)	2.1×
Charles River (CRL)	1.9×
Quest Diagnostics (DGX)	1.9×
IQVIA (IQV)	1.7×
GE HealthCare (GEHC)	1.6×
Labcorp Holdings (LH)	1.6×
HCA Healthcare (HCA)	1.4×
Solventum (SOLV)	1.4×
Viatris (VTRS)	1.1×
Baxter International (BAX)	0.8×
DaVita (DVA)	0.7×
Henry Schein (HSIC)	0.6×
Universal Health Services (UHS)	0.6×
UnitedHealth Group (UNH)	0.5×
Teladoc Health (TDOC)	0.4×
Elevance Health (ELV)	0.3×
McKesson (MCK)	0.3×
Cigna (CI)	0.3×
CVS Health (CVS)	0.2×
Cardinal Health (CAH)	0.2×
Cencora (COR)	0.2×
Humana (HUM)	0.2×
Molina Healthcare (MOH)	0.2×
Centene (CNC)	0.1×

P/S Ratio for Climb Bio (CLYM)

P/S Ratio daily chart for Climb Bio (CLYM)

Historical P/S Ratio for Climb Bio (CLYM) from 2020 to 2025

About P/S Ratio at Climb Bio (CLYM)

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

Climb Bio (CLYM) Key Financials

P/S Ratio daily chart for Climb Bio (CLYM)

Historical P/S Ratio for Climb Bio (CLYM) from 2020 to 2025

About P/S Ratio at Climb Bio (CLYM)

Sector peers by P/S Ratio — chart

Sector peers by P/S Ratio — table

Frequently asked questions

+What is Climb Bio's P/S ratio?

+How is the P/S ratio calculated?

+What is the P/S ratio?

+What is a good P/S ratio for Climb Bio?

+Why does Climb Bio's P/S ratio change over time?

+Why is Climb Bio's P/S ratio not available?

Climb Bio (CLYM) Key Financials